GARS1 and infection: Specifically, Lycobetaine and Scutellarein reduced viral titers and infection rates for both A-type and B-type influenza viruses, confirming GlyRS as an effective target for antiviral therapy and providing new insights into the development of broad-spectrum antiviral drugs.